The Competition Board has opened an investigation into the economic integrity consisting of Biota Herbal Drugs and Cosmetic Laboratories Inc., Derma Cos Drug Medical and Cosmetic Industry and Internal Trade Inc., and Derma-Cos Cosmetic Industry Trade Import and Export Limited Company. According to the announcement on the Competition Board’s website, this economic integrity operates in the pharmacy channel with the Bioxcin, Nutraxin, Bioder, and Biobaby brands, and in the market channel with the Bioblas and Restorex brands. The Board decided to initiate an investigation to determine whether the economic integrity violated the Law on Protection of Competition by determining the resale price of their distributors and/or restricting online sales. The investigation decisions taken by the Board do not imply that the enterprises or business associations under investigation have violated the law and face or will face sanctions.